s.perrin

TL2 Moderator · Córdoba

Contributes reviews on supplier material. Based in Córdoba.

Joined 12 November 2024 · last posted 3d

87Posts here

0Topics

1Solutions

739Likes received

466Likes given

19Badges

170Days visited

2.2kPosts read

Recent activity

Full stream

What steady state means for the decision to escalate Replied, post #35 · Practice › Dosing & titration · 25 Jul 2026 · 0 likes Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you…
CJC-1295 with and without DAC: what the modification does Replied, post #116 · Compounds › Secretagogues & GH axis · 19 Jul 2026 · 1 like Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is…
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #75 · Practice › Dosing & titration · 18 Jul 2026 · 0 likes Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a…
[2026 update] Documenting an adverse event properly Replied, post #13 · Safety › Adverse events · 18 Jul 2026 · 23 likes Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family history of MTC or multiple endocrine neoplasia type 2.…
I joined for one answer and stayed for a year — what changed my mind Replied, post #84 · Start Here › Welcome · 15 Jul 2026 · 11 likes The FAQ link in the sidebar is maintained and worth ten hours of forum browsing. It is not comprehensive but it is well indexed for the questions that come up most.
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #69 · Outcomes › Progress reports · 3 Jul 2026 · 6 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Replied, post #17 · Evidence › Journal club · 26 Jun 2026 · 8 likes On post #13 — agreed on the reasoning, with one qualification. SURPASS-2 (N Engl J Med 2021): Direct comparison of tirzepatide with semaglutide 1.0 mg. The 1.0 mg dose…
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Replied, post #60 · Evidence › Journal club · 26 Jun 2026 · 29 likes Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #17 · Analytics › Home & field testing · 21 Jun 2026 · 0 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
Personal or family history of medullary thyroid carcinoma — what changed since Replied, post #78 · Safety › Contraindications · 18 Jun 2026 · 22 likes Allergy to the specific compound: true allergy is rare but possible. Any prior allergic reaction to the same compound or to structurally similar peptides warrants…
Submitting a sample: the process end to end Replied, post #21 · Sourcing › Independent verification · 16 Jun 2026 · 17 likes post #20 answers the question as asked. The question underneath it is different. Repeat testing: if you want to verify the same lot a second time, testing with a…
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #7 · Analytics › Home & field testing · 16 Jun 2026 · 2 likes Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at extremes and the correlation depends on the exact conditions…